CINGULATE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6611 USD | -4.59% |
|
-8.54% | -91.36% |
| 05-21 | FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD | CI |
| 05-08 | Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 4.57M | - | - | - | - | - | |
| 53.67B | - | |||||
| 38.86B | ||||||
| 38.76B | ||||||
| 27.27B | ||||||
| 25.91B |
- Stock Market
- Equities
- CING Stock
- Charts Cingulate Inc.
- Sector Chart
